News & Media

Roche to Buy InterMune for $8.3 Billion

The price, $74 a share, represents a 38 percent premium to InterMune’s closing price on Friday and a 63 percent premium to the price on Aug. 12, before news reports that InterMune might be acquired.

The acquisition was announced during a flurry of pharmaceutical deals and attempted deals. About $87 billion in pharmaceutical acquisitions were made in the first half of this year, eclipsing the total for all of 2013, according to Evaluate, a research company. The total for the first half does not include the $54 billion acquisition of Shire by AbbVie, which was formally announced in July.

InterMune, based in Brisbane, Calif., has one product on the market: a drug called pirfenidone to treat idiopathic pulmonary fibrosis, a fatal scarring of the lungs.

Sales of Esbriet were $35.7 million in the second quarter, but some analysts expect annual revenues to eventually exceed $1 billion.

for the rest of the article, go to: http://dealbook.nytimes.com/2014/08/24/roche-to-buy-drug-maker-intermune-for-8-3-billion/?_php=true&_type=blogs&_php=true&_type=blogs&_r=1

 

Back

Subscribe to the BAM Newsletter

Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.

Subscribe